March 28, 2022: “EnteroBiotix Limited (“EBX”), a clinical stage biotechnology company focussed on developing best-in-class full-spectrum microbiome therapeutics announced the initiation of a multi-centre randomised double-blind placebo controlled Phase 2 clinical trial.
The trial has been designed to evaluate EBX-102, the company’s lead product candidate, for the treatment of liver cirrhosis and hepatic encephalopathy (“HE”).
EBX-102 is presented in the form of an orally administered capsule that contains diverse full-spectrum microbial ecosystems that are intended to restore microbial ecology and act in concert to target multiple key disease pathways.
The Phase II study, named ‘IMPuLCE’ (Intestinal Microbiota Product in Liver Cirrhosis and Encephalopathy) intends to enrol 56 patients with liver cirrhosis across sites in the United Kingdom. The trial evaluates EBX-102 in patients with cirrhosis and HE being treated with standard of care medications, including Rifaximin.”
https://www.enterobiotix.com/news/phase-2-study-of-microbiome-drug-ebx-102
